Home › Colorectal Cancer › NCT04701476
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
RecruitingPhase 2
An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations * mCRC progressed on at least two lines of standard chemotherapy; or * NSCLC progressed on chemotherapy and an immune checkpoint inhibitor * Measurable disease * ECOG 0-1 * At least 4 weeks from prior chemotherapy and free from chemo-related toxicity * Adequate organ function Exclusion Criteria: * Prior organ transplantation * Liver metastasis more than 50% * Oxygen saturation less than 92% in room air * Prior autoimmune disorder * CNS metastasis * Major GI bleeding in the last 2 months
About the study
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
What is being tested
- TATE and pembrolizumab (drug)
- TAS-102 pill (drug)
- Regorafenib Pill (drug)
Sponsor: Teclison Ltd. · Participants: 110 · Started: May 20, 2021
Contact the study team
- Ray Lee, MD. PhD. · Phone: 8043341076
Official record on ClinicalTrials.gov — NCT04701476
Locations in the U.S.
| California | University of California, Irvine Medical Center, Orange |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.